BioCentury | Oct 19, 2018
Financial News

PhaseBio, Osmotica price NASDAQ IPOs well below range

Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced IPOs well below their proposed ranges late Oct. 17. PhaseBio trading ended flat at $5 on Oct....
BioCentury | Oct 18, 2018
Financial News

PhaseBio, Osmotica price IPOs well below range

Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced IPOs well below their proposed ranges late Wednesday. PhaseBio trading ended flat at $5 on Thursday, while...
BioCentury | Aug 15, 2016
Clinical News

subcutaneous PB1046: Phase IIa started

PhaseBio began a double-blind, placebo-controlled, dose-escalation, U.S. Phase IIa trial of once-weekly subcutaneous PB1046 over 4 weeks. The first part will test PB1046 in about 28 patients with stable heart failure with reduced ejection fraction...
BioCentury | May 2, 2016
Regulation

Just to confirm

A narrow panel vote on data from a surrogate endpoint for eteplirsen from Sarepta Therapeutics Inc. has left the door open for accelerated approval for Duchenne muscular dystrophy caused by mutations amenable to exon 51...
BioCentury | Feb 4, 2016
Distillery Therapeutics

Therapeutics: Vasoactive intestinal peptide receptor 2 (VPAC2)

...longer plasma half-life (24 minutes) than vasoactive intestinal peptide, the endogenous ligand of VPAC2 and VPAC1...
BioCentury | Apr 27, 2015
Clinical News

PhaseBio preclinical data

In a mouse model of DMD, thrice-weekly 1.5 mg/kg subcutaneous PB1046 for 32 weeks ameliorated DMD myopathies, slowed cardiac deterioration and protected skeletal muscle by reducing fibrosis vs. saline-treated controls. Data were presented at the...
BioCentury | Mar 13, 2015
Financial News

AstraZeneca leads PhaseBio series C

PhaseBio Pharmaceuticals Inc. (Malvern, Pa.) raised $20 million in the first tranche of a planned $40 million series C round led by AstraZeneca plc (LSE:AZN; NYSE:AZN). Existing investors New Enterprise Associates, Hatteras Venture Partners, Johnson...
BioCentury | Nov 17, 2014
Company News

NuView, Otsuka Pharmaceutical deal

...NuView granted Otsuka exclusive, worldwide rights to develop and commercialize NuView's genomic-based vasoactive intestinal peptide receptor 1 (VPAC1) diagnostic biomarker...
...subsidiary to manufacture the diagnostic biomarker. The partners plan to develop the biomarker as a VPAC1-specific...
...coming months." The partners could not be reached for details. NuView, which retains rights to VPAC1...
BioCentury | Jun 24, 2013
Clinical News

Vasomera: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial in 40 patients with stage 1 or 2 essential hypertension showed that single ascending-doses of subcutaneous Vasomera were generally well tolerated with no clinically relevant cardiovascular safety signals...
BioCentury | Mar 11, 2013
Clinical News

Cu-64-TP3805 diagnostic data

...Inc. , Park City, Utah Product: Cu-64-TP3805 ( NVB-64 ) Business: Diagnostic Molecular target: Vasoactive intestinal peptide receptor 1 (VPAC1...
Items per page:
1 - 10 of 20